Clinical Trial Update: The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed duloxetine for mood, quality of life, and cognitive functioning in glioblastoma patients; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Major Depressive Disorder

Drugs mentioned

• Duloxetine (DULOXETINE)

Snippet

Sponsor: michal roll | Conditions: Depression | Phase 3 | Status: TERMINATED